Grants

EU co-funded 2019-2023

We aim to produce high yields of novel HBV/HCV antigens with superior immunogenic properties in plants and mammalian cells, based on innovative molecular design and establish in premiere an advanced biotechnological platform for production of best vaccine candidates antigens in algae.

EU co-funded 2019-2022

Starting 01.06.2019, the Institute of Biochemistry of the Romanian Academy is implementing the EMBED project, funded by UEFISCDI (contract 103, from 01.06.2019), through the ERA-NET COFUND-NEURON III grant call. The project aims to assess the shared molecular links between pre- and post-natal, metabolic and psychosocial stress, and the risks of depression later in life, and its duration will be 36 months.

EU co-funded 2016-2021

Starting 02.09.2016, the Institute of Biochemistry of the Romanian Academy is implementing the project “Multi-omics prediction system for prioritization of gerontological interventions”, co-funded through European Fund for Regional Development, in accordance with the funding contract signed by the Ministry of National Education and Scientific Research. The total funding for the project is 8.524.757,50 lei, of which 8.502.557,50 lei represent non-reimbursable funding. The project’s duration is 48 months.

EU co-funded 2014-2017

Hepatitis B (HBV) and C viruses (HCV) are important human pathogens resulting in more than 500 million people being currently carriers. Sadly, Romania has the highest prevalence of HBV/HCV infections among the EU countries (up to 7% of the population). Chronically infected patients of HBV and HCV are at high risk to develop severe liver diseases, such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).

EU co-funded 2014

Hepatitis C virus (HCV) is an important human pathogen that infects the liver and establishes chronic infection in the majority of cases, leading to cirrhosis and hepatocellular carcinoma over the course of many years. Despite recent progress, details of the HCV life cycle are still missing, with the HCV assembly process being particularly poorly understood.

EU co-funded 2014

HCV is a major cause of chronic hepatitis worldwide. A better understanding of the HCV life cycle is needed to develop new treatments against this virus. A peculiarity of HCV is the crucial role played by both structural and non-structural proteins in the assembly process. Indeed, practically all HCV proteins have been shown to be involved in the virion assembly process. The present project aims to characterize the spatial and temporal relationship between all the viral proteins during viral assembly.

EU co-funded 2010-2013

Programul Postdoctoral "Biotehnologii Celulare si Moleculare cu Aplicatii in Medicina", se adreseaza tinerilor cu diploma de doctor in biologie, chimie, fizica, medicina si informatica - interesati de burse de cercetare Post Doctorala la standarde europene.

EU co-funded 2010-2012

Scopul PROCERA este de a dezvolta infrastructura IBAR pentru cresterea capacitatii de cercetare-dezvoltare C-D in domeniul biochimiei si biologiei moleculare pe plan national, precum si a competitivitatii cercetarii stiintifice romanesti la nivel european.

EU co-funded 2010

Începând cu data de 16.06.2010, Institutul de Biochimie beneficiază de asistenţă financiară nerambursabilă pentru implementarea proiectului “Întărirea capacităţii administrative”, în baza contractului de finanţare nr. 167/16.06.2010 semnat cu Organismul Intermediar ANCS Bucureşti.

EU co-funded 2007-2011 Framework program 6, Marie Curie Research Training Network

Enzymatic characterization of both mEya3 and hEya1 to identify the similarities and differences between these two proteins with relatively low sequence homology.

International 2022-2024

The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.

International 2019-2022 https://acad.ro/relExterne/pag_relExt.htm

The project is agreed as a joint collaboration among IBAR and ATOMKI, UD and IFIN-HH is a cost free participant. There are two main directions envisaged by the proposed project: receptors mapping and therapy, using an affibody against HER2 receptor, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establish labeling procedures; c) ex vivo and/or in vivo testing of optimal compounds.

National 2021-2023

This project aims to understand the molecular events associated with protein aggregation and how a Golgi located protein along with the UPR pathway modulate this process. Model proteins such as IL-1β and α-synuclein, previously shown to aggregate will be employed for these studies. Achieving the objectives of this project should facilitate the understanding of the signaling pathways and the sequence of events correlating the stress sensing machinery with cytoplasmic proteome instability.

National 2020-2022 PN-III-P1-1.1-PD-2019-1278/PD183

This project aims to develop new strategies to improve the capacity of antigen presenting tumor cells to activate cytotoxic T cells and hamper immune escape mechanisms in cancer.

National 2020-2022

The project aims to analyze and compare the age-related transcriptomics signatures in variuos tisues, both in healthy and pathological individuals, in order to identify shared or unique aging signature that drive aging or age-related diseases.

National 2020-2022

This project aims to develop a sensitive high-throughput screening platform by generating an endogenously tagged interleukin-1β reporter cell line by CRISPR-Cas9 technology, able to monitor stimulated IL-1β secretion with the purpose to identify new chemical compounds with anti-inflammatory activity that will be validated in primary macrophages and a mouse model for sepsis.

National 2020-2022 PED

The principal goal of this project is the development of a new class of small molecule inhibitors (SMIs) targeting TG2-FN interaction, which is currently in the phase of lead optimization, translatable to clinical use for prevention of ovarian cancer dissemination, either alone or in combinations.

National 2020-2022 TE

The overall goal of the current project is to understand the impact of tissue transglutaminase (TG2) targeting in the context of ovarian cancer (OC) tumor microenvironment (TME). Our aproach is aimed at testing the hypothesis that interventions in targeting TG2 in the OC TME will disrupt pro-tumorigenic signaling cross-talk within tumors.

National 2020-2022

The project aims to experimentally develop an integrated and automated solution for screening drugs and genetic interventions for neurodegenerative diseases, using the nematode C. elegans and ageing-related data.

National 2017-2019

Bone loss represents one of the most important health problems experienced by Space travelling astronauts. Microgravity produces deterioration of the skeleton due to lack of mechanical loading thus affecting both muscle and bones. Tendons stiffness decreases, muscle fibres atrophies and attenuates their metabolic capacity, whileprogressive cartilage loss occurs.

National 2017-2019

This project aims to address a number of structural aspects related to key elements of the plant immune system and its pathogen interactors using a combined approach intricating experimental and computational steps. To this end we intend to build on our previous results in the field and further develop experimental, bioinformatics and molecular modeling methods appropriate for solving the specific problems implied by this proposal.

National 2017-2019

Musculoskeletal disorders affect 1 in 7 people and fractures alone affect 1 in 50 people annually while 10% of bone injuries fail to heal. Our present proposal aims to test for the first time the potential of fibroblast growth factor-2 (FGF2), to be administered as a stimulatory drug to enhance bone regeneration.

National 2016-2020

The receptor for advanced glycation end-products (RAGE) and its ligands are important players in pathological conditions such as diabetes, neurodegenerative diseases, and cancers. RAGE is a cell surface molecule of the immunoglobulin superfamily. Alternatively spliced variants lacking either only the intracellular domain or both the intracellular and the transmembrane domains are also expressed in some tissues.

National 2016-2019

Societatea contemporana se afla in mijlocul unei epidemii globale de diabet zaharat tip 2. Aceasta boala este caracterizata de concentratii patologic crescute de glucoza in sangele pacientilor datorita productiei, secretiei si utilizarii inadecvate a insulinei - hormonul principal care regleaza concentratia de glucoza serica. Ne propunem sa generam linii reporter stabile ce pot fi utilizate pentru cuantificarea insulinei secretate.

National 2013-2015

A considerable fraction of all newly synthesized secretory polypeptides fail to attain their native conformation due to mutations, transcriptional and translational errors, folding defects or endoplasmic reticulum (ER) stress conditions.

National 2012-2015

A detailed knowledge of the mechanisms of antigen processing and presentation is essential to optimize cancer vaccination. known as Endoplasmic Reticulum Associated Degradation (ERAD). Non cytosolic misfolded proteins, synthesized at the endoplasmic reticulum are degraded to peptides by a complex machinery Cancer immunotherapy aims at harnessing the resources of the immune system to treat cancer.

National 2011-2016 PN-II-ID-PCE-2011-3-0743

Synthesis of the catalytic domain of ancestral PTP and its characterization both in vitro and in vivo.

Sponsorship 2017-2018

The Systems Biology of Aging team is grateful for the "Microsoft Azure for Research" sponsorship awarded to our group. We have received cloud computing resources worth the equivalent of 20,000$ credits, and this has greatly helped us to speed up some of our research projects.

Sponsorship 2017-2018

Molecular modeling of a set of peptides that can disrupt the GluA2-Cterm complex with STEP (Complex A) or BRAG2 (ComplexB).